Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase
Kenneth R. Hallows, Viswanathan Raghuram, Bruce E. Kemp, Lee A. Witters, J. Kevin Foskett
Kenneth R. Hallows, Viswanathan Raghuram, Bruce E. Kemp, Lee A. Witters, J. Kevin Foskett
View: Text | PDF
Article

Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase

  • Text
  • PDF
Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is an ATP-gated Cl– channel that regulates other epithelial transport proteins by uncharacterized mechanisms. We employed a yeast two-hybrid screen using the COOH-terminal 70 residues of CFTR to identify proteins that might be involved in such interactions. The α1 (catalytic) subunit of AMP-activated protein kinase (AMPK) was identified as a dominant and novel interacting protein. The interaction is mediated by residues 1420–1457 in CFTR and by the COOH-terminal regulatory domain of α1-AMPK. Mutations of two protein trafficking motifs within the 38–amino acid region in CFTR each disrupted the interaction. GST-fusion protein pull-down assays in vitro and in transfected cells confirmed the CFTR-α1-AMPK interaction and also identified α2-AMPK as an interactor with CFTR. AMPK is coexpressed in CFTR-expressing cell lines and shares an apical distribution with CFTR in rat nasal epithelium. AMPK phosphorylated full-length CFTR in vitro, and AMPK coexpression with CFTR in Xenopus oocytes inhibited cAMP-activated CFTR whole-cell Cl– conductance by approximately 35–50%. Because AMPK is a metabolic sensor in cells and responds to changes in cellular ATP, regulation of CFTR by AMPK may be important in inhibiting CFTR under conditions of metabolic stress, thereby linking transepithelial transport to cell metabolic state.

Authors

Kenneth R. Hallows, Viswanathan Raghuram, Bruce E. Kemp, Lee A. Witters, J. Kevin Foskett

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Cyclic AMP-activated CFTR whole-cell conductances in Xenopus oocytes in ...
Cyclic AMP-activated CFTR whole-cell conductances in Xenopus oocytes in the presence or absence of AMPK subunits. Oocytes were injected with 20 ng CFTR cRNA ± 5–15 ng total of AMPK subunits. Two-electrode voltage clamp measurements were performed 2–4 days after injections. (a) Representative traces of CFTR Cl– conductance activation in presence or absence of coexpressed AMPK holoenzyme. Dashed vertical line indicates when oocytes were perfused with solution containing 10 μM forskolin plus 1 mM IBMX to stimulate CFTR Cl– conductance. μS, microsiemens. (b) Relative stimulated CFTR conductances in oocytes expressing CFTR plus different AMPK subunits. Bars represent the mean change in conductance (± SEM) of voltage-clamped oocytes expressing CFTR with indicated AMPK subunits relative to that of oocytes expressing CFTR alone from the same batch (horizontal dashed line at 100%). Number of replicates for each condition and P values compared with the CFTR alone condition are shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts